Partnerships

AVERSION®

Acura’s lead product, OXAYDO™ (oxycodone HCI, USP) Tablets CII, was approved for marketing by the United States Food and Drug Administration (FDA) on June 17, 2011. OXAYDO™ represents the first immediate-release oxycodone product approved by the FDA that applies Acura’s AVERSION® Technology. AVERSION® is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules designed to address some common methods of product tampering.

On January 8, 2015, Acura entered into a licensing and collaboration agreement with Egalet US, Inc. and Egalet Ltd. granting them exclusive worldwide rights to commercialize OXAYDO™. Acura and Egalet are currently working to transition OXAYDO™ for commercial launch in the U.S. as soon as commercially practical.

Acura has developed several other tamper-resistant opioid products using AVERSION® Technology. The Company is currently considering commercialization opportunities for these products and product candidates.

Other AVERSION® Products in Development

Acura has developed several other tamper-resistant opioid products using AVERSION® Technology. The Company is currently considering commercialization opportunities for these products and product candidates.

IMPEDE®

Acura is currently marketing NEXAFED®, its own 30mg immediate-release formulation of pseudoephedrine hydrochloride using its IMPEDE® Technology. Acura aims to develop a full line of immediate and sustained-release products utilizing the IMPEDE® Technology for commercialization in the United States.

Acura seeks to establish partnerships outside the U.S. for products using its IMPEDE® Technology. Acura considers partnerships within the U.S. for its IMPEDE® Technology with companies that support our goal of making abuse deterrent formulations a standard of care in U.S. pharmacies and/or provide technical assistance for hard to develop formulations.